KaloBios (KBIO) is now in Oversold Territory - Tale of the Tape

by Zacks, Benzinga Contributor

April 3, 2014 10:04 AM | 1 min read | Make a Comment

KaloBios Pharmaceuticals Inc's ( KBIO ) share price has entered into oversold territory with an RSI value of 29.9. The Zacks Consensus Estimate for KaloBios for the full year period has improved 8 cents over the past two months to -$1.40 per share. Currently, KaloBios has a Zacks Rank #2 (Buy), suggesting that now might be a good time to get in on ( KBIO ) after its recent drop.

KALOBIOS PHARMA KBIO: Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research

Market News and Data brought to you by Benzinga APIs

Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!